The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
https://finance.yahoo.com/quote/2F5.F?p=2F5.F&.tsrc=fin-srch
Frankfurt market actually closed up 16.5% before the bad news was announced in the US. So MC is still showing as €508m (£460m).
Will be many broken hearts and tears tomorrow when market opens...
Kin”ell.
Peeps slowly Understanding how a dividend works
Look. The only reason for Flu-v delay was Woody being at 29.9% They loved HVO but it wasn’t their job to take it over .
And see their judgement - DDDD, SNG etc
Sharp but wrong time and over exuberant- like us PIs - apart from the 5% ters
Yep Balman,
CF sees things differently he is a businessman so does not get attached to a drug/ platform.
Think one of issues with previous management was Flu V was their baby but they simply did not have the money to take through to p3 and did not want to let it go.
They never seemed to want to reduce expenditure by sacking folk so was always loss making.
You can see CF agenda is make it work and profitable.Complete change of mindset
I feel for the shareholders of Biondvax as well as the team who have worked on this for the last 15 years.
https://finance.yahoo.com/quote/BVXV?p=BVXV&.tsrc=fin-srch
From a MC of $460m to just under $60m and possibly falling further on Monday - ouch.
Just goes to show the high level of risk involved in trying to get a drug/vaccine to market. The team obv must have thought they were onto a winner to proceed with p3 after 1 and 2.
So even though we have a p3 ready vaccine, I believe CF is doing the right thing in wanting to sell it rather than take the risk and conduct p3 trials under Open Orphan.
I think DG is right news not reported , I wonder why ?
Ivyspivey
Good point.
It did Ivy. Just lazy journalism - makes my blood boil :-).
As you say Demon G the Biondvax news was nothing to do with the 8% rise as was simply imo a bounce back due to being oversold on an excellent earlier RNS re confirming the govt contract.
Did the news not come in after the market closed
PS If you look at phase 2 results for Flu V you will note that it was the Adjuvanted Group that demonstrated the superiority vs the placebo. By using an adjuvant you increase the potency but with less risk reverting to virulence for new strains etc.
Nice article Moniman,
It highlights the issue with traditional Vax.
They work on predicting the strains in circulation so HVN etc the predicted antigens are added to the Vax which stimulates a humoral AB response.
As Flu V targets the cell via the 4 mechanisms it produces a much stronger cell mediated response involving T cells etc and that means if the antigens mutate to form new strains or revert in some way then the Vax will still protect hence the universal Vax
Looking forward to Cathal's presentation on Thursday, I'm sure he give his thoughts on the Biondvax news and how this can position Imutex going forward, leaves Flu-V as a real front runner for a universal flu vaccine
Apologies if you did BM. I’ve not had time to read through all the posts. Great minds think alike, haha.
Love to hear what cathal has to say now about imutex
That’s a sooooper dooooper article moniman....well spotted.
Did I not say that earlier DG.
Hi moniman,
Thanks for the link ! I particularly liked Plegezuelos' closing observation (in early March, remember, when COVID was still something of a novelty to the layperson) :
.."The methods used to develop FLU-v also are being utilized to develop potential vaccines against HIV, mosquito-borne pathogens, hepatitis B and C, and rotavirus, Pleguezuelos said.
The same sort of platform also could be used to develop a coronavirus vaccine, she added".
" You sell the sizzle, not the sausage.."
ATB
Hi barwickman,
You could well be right , I haven't followed closely ...we're deffo agreed on 'the more the merrier' !
ATB
What a lot of rubbish! The 8% share rise had not hi BG to do with Biondvax! P*ss poor journalism!
I've not seen this article from USA before, says a lot of good things about Flu v, also Flu v is totally different technology to Biondvax failure of the drug. Who else is prepared to wait another 15years and $400million to catch up with Imutex's Flu v vaccine? Monday will give us some idea where this is all going...
https://www.usnews.com/news/health-news/articles/2020-03-09/is-a-universal-flu-vaccine-on-the-horizon
Also, if I were a Biondvax shareholder I would be interested in buying Imutex, just now they are worthless, however, with a fundraiser in the States which they would embrace they could get a second shot at the prize, thus, not wasting $400M of investment and 15 years of expertise. Just a thought.
To the more knowledgeable out there, as Seek own 51% are they leading the sale or has Cathal been given the reins on this one? Also, if and when they start talks do they need to notify the market?
Seems to me imutex has just doubled in value now that we are out in front. What's a billion dollars to the biggest pharmas for the end prize
RoscoRed...have you suddenly become an expert on whether Flu v is worth more or less just because the competitors drug is a failure. You don't base their failure on the value of our product. I've never heard such nonsense. In that case as soon one of the Covid 19 vaccine fails all the dozens of others will throw the towel in. I'll just get my crystal ball out and see what OO is worth or maybe I'll just leave it up to Cathal and his team of Experts!
I’m hoping relatively cheaply is 500 m